WHO Member States Extend Pandemic Agreement PABS Annex Talks
WHO Member States have agreed to extend negotiations on the Pathogen Access and Benefit Sharing (PABS) annex to the WHO Pandemic Agreement. Discussions will resume in late April and early May 2026, ahead of consideration by the World Health Assembly.
Exchange Coverage Remains Near Record High with 23.1 Million Enrolled in 2026
The Centers for Medicare & Medicaid Services (CMS) reported that 23.1 million consumers selected or were automatically re-enrolled in coverage through the Health Insurance Exchanges for plan year 2026. The report highlights the impact of CMS enforcement actions to prevent fraud, which resulted in the removal of nearly 1.5 million improper enrollments.
Center for Scientific Review; Notice of Closed Meetings
The National Institutes of Health, through the Center for Scientific Review, has issued a notice announcing upcoming closed meetings. These meetings are part of the review process for grant applications and are scheduled to occur on April 22, 2026.
National Institute on Minority Health and Health Disparities; Notice of Partially Closed Meeting
The Department of Health and Human Services, through the National Institutes of Health, has issued a notice regarding a partially closed meeting of the National Institute on Minority Health and Health Disparities. The meeting is scheduled for May 19, 2026.
FDA Guidance on Incorporating Patient Preference Information
The Food and Drug Administration (FDA) has issued a notice announcing the availability of its final guidance on incorporating voluntary patient preference information throughout the total product life cycle. This guidance is intended for industry, FDA staff, and other interested parties.
Advisory Board on Radiation and Worker Health Meeting Notice
The Centers for Disease Control and Prevention (CDC) has issued a notice announcing a meeting of the Advisory Board on Radiation and Worker Health. The meeting is scheduled for March 30, 2026, and the public comment period for this notice closes on April 15, 2026.
Advisory Board on Radiation and Worker Health Meeting Notice
The Centers for Disease Control and Prevention announced a meeting of the Advisory Board on Radiation and Worker Health, Subcommittee for Procedure Reviews. The meeting is scheduled for June 5, 2026, and will focus on procedure reviews.
USP Develops Digital Quality Standards for Workflows
The U.S. Pharmacopeia (USP) announced the development of digital reference standards (dRS) and digitally structured compendial methods (dDS) to integrate quality standards into digital workflows. This initiative aims to enhance consistency, reduce risk, and strengthen regulatory confidence for manufacturers adopting digital technologies in drug development and manufacturing.
USP Dietary Supplement Program Recognized by Amazon's Compliance Fast-Track Program
The U.S. Pharmacopeia (USP) has been named a participating certifier in Amazon's new Compliance Fast-Track Program for dietary supplements. This recognition means products bearing the USP Verified Mark will be automatically accepted by Amazon, streamlining market access for compliant manufacturers.
USP Granted Patent for Automated NMR System
The U.S. Pharmacopeia (USP) has been granted a patent by the United States Patent and Trademark Office for an automated nuclear magnetic resonance (NMR) system. This patented approach aims to make NMR technology more reliable and easier to use by automating spectral processing and comparison to USP reference standards.
Iowa Methamphetamine Seizures Rise
The DEA Omaha Division reported a significant increase in methamphetamine seizures in Iowa, with 250 pounds confiscated in less than four months. The notice encourages the public to learn more about the facts surrounding these seizures.
DEA Seizes 900,000 Fentanyl Doses and 500,000 Pills in L.A.
The DEA announced the seizure of 900,000 potentially lethal doses of fentanyl and 500,000 counterfeit pills in Los Angeles. This action, taken in coordination with law enforcement partners, removed a significant quantity of dangerous drugs from circulation.
Fugitive Wanted for Cocaine Conspiracy
The DEA is seeking the public's assistance in locating Abraham Vivanco Leon, a fugitive wanted for conspiracy to distribute and possess with intent to distribute cocaine. Information and tips can be submitted through the DEA website and to the U.S. Marshals Service.
FDA Document on Uterine Lavage and Live Births
The Food and Drug Administration (FDA) has issued a document concerning uterine lavage and its relation to live births. This notice provides information on the topic, likely for public awareness or to inform stakeholders in the healthcare and pharmaceutical sectors.
FDA Complaint Document Closed for Comments
The Food and Drug Administration (FDA) has closed a complaint document for public comments. The document, authored by CTP, is available for download via a link on regulations.gov. No specific details about the complaint's content or its regulatory impact are provided.
FDA Final Response
The Food and Drug Administration (FDA) has posted a final response related to docket FDA-2022-P-2644-0046. The document, authored by CDRH, is available via the provided URL and download link.
FDA Complaint Filed and Closed for Comments
The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint, filed on March 27, 2026, is available for review and submission of feedback.
FDA Acknowledgement Letter to Steranco Healthcare Pvt. Ltd.
The Food and Drug Administration (FDA) has issued an acknowledgement letter to Steranco Healthcare Pvt. Ltd. The letter confirms receipt of documentation related to a submission. No specific details regarding the nature of the submission or any required actions are provided in the available information.
Mifepristone Clinical Indications Systematic Review Document
The Food and Drug Administration has issued a systematic review document regarding the clinical indications for mifepristone. This document outlines the FDA's review process and findings related to the drug's approved uses.
PGT-A using human in vivo - Part 1 & 2
The Food and Drug Administration (FDA) has made available two attachments related to the first PGT-A (Preimplantation Genetic Testing for Aneuploidy) performed using human in vivo. These documents, authored by CDER, provide supplementary information on this specific application of PGT-A.
Preeclampsia Risk and IVF Cycles Guidance
The Food and Drug Administration (FDA) has issued new guidance regarding the risk of preeclampsia associated with in vitro fertilization (IVF) cycles. This guidance aims to inform healthcare providers and patients about potential risks and management strategies.
FDA Complaint Filed and Closed for Comments
The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint is related to the Center for Tobacco Products (CTP) and has a filing date of March 27, 2026.
FDA Complaint Document Details
The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document is available for review on the regulations.gov portal, with a specific detail date of March 27, 2026. No further details on the nature of the complaint or its implications are provided in the initial posting.
FDA Complaint Document Posted
The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. This document is available for public review and comment, with a specific deadline for submissions.
FDA Complaint Filed and Closed for Comments
The Food and Drug Administration (FDA) has filed a complaint and opened it for public comment. The complaint, filed on March 27, 2026, is available for review and submission of feedback through the Regs.gov portal.
Appco Pharma LLC Suitability Petition
The Food and Drug Administration (FDA) has received a suitability petition from Appco Pharma LLC. The petition is related to drug manufacturing and regulatory filings.
FDA Complaint Document
The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document, authored by CTP, is available for review on Regulations.gov. No specific compliance actions or deadlines are indicated.
FDA Acknowledgement Letter to Charlene Peters
The Food and Drug Administration (FDA) has issued an acknowledgement letter to Charlene Peters regarding a submission. The letter, authored by CDER, confirms receipt of the document. No specific details about the submission's content or regulatory implications are provided.
FDA Complaint Document
The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document, authored by the Center for Tobacco Products (CTP), is available for review and download via the regulations.gov portal.
FDA Supporting Material for Proposed Rule
The Food and Drug Administration (FDA) has posted supporting material for a proposed rule on March 27, 2026. This material is associated with docket number FDA-2026-P-3242. The posting provides additional context and data related to the proposed regulatory action.
Citizen Petition from Charlene Peters
The Food and Drug Administration (FDA) has received a citizen petition from Charlene Peters. The petition is currently available for review, with a redacted version provided for public access.
FDA Complaint Document Posted for Comments
The Food and Drug Administration (FDA) has posted a complaint document for public comment, with the comment period closing on March 27, 2026. The document is related to a complaint filed by CTP.
FDA Background Material for Docket FDA-2026-P-3242
The Food and Drug Administration (FDA) has posted background material related to docket FDA-2026-P-3242. This material is available for public review and does not impose new regulatory requirements.
FDA Complaint Docket FDA-2026-H-3040
The Food and Drug Administration (FDA) has opened a new complaint docket, FDA-2026-H-3040, related to a complaint filed by CTP. No documents are currently available for viewing or download within this docket.
FDA Complaint Filed for Public Comment
The Food and Drug Administration (FDA) has opened a public comment period for a filed complaint related to its regulations. The complaint, authored by CTP, is available for review and download on regulations.gov. This action initiates a consultation period for interested parties to provide feedback.
FDA Complaint Document
The Food and Drug Administration (FDA) has posted a complaint document to the Federal Docket Management System. The document, authored by CTP, is available for review and download via the provided links.
Notice of Laboratory Assessment Requests Renewal
The Food Safety and Inspection Service (FSIS) is requesting a renewal of an approved information collection for non-FSIS laboratories that test food samples during illness outbreaks and recall investigations. There are no changes to the existing collection, and the approval is set to expire on August 31, 2026.
Notice: Renewal of Voluntary Destruction of Imported Meat, Poultry, and Egg Products Information Collection
The Food Safety and Inspection Service (FSIS) is announcing its intention to renew an approved information collection regarding the voluntary destruction of imported meat, poultry, and egg products. This is a renewal with no changes to the existing collection, which is approved until July 31, 2026. The agency is requesting public comments on this renewal.
EMA Recommends Imdylltra for Relapsed Small Cell Lung Cancer
The European Medicines Agency (EMA) has recommended marketing authorisation for Imdylltra (tarlatamab) for adults with relapsed extensive-stage small cell lung cancer. This recommendation is based on Phase 3 trial data showing improved overall survival and progression-free survival compared to standard of care.
EMA Recommends Restricting Tecovirimat SIGA for Mpox Treatment
The EMA's Committee for Human Medicines has recommended restricting the use of Tecovirimat SIGA for the treatment of mpox. Clinical trials showed the medicine was not effective in healing lesions faster than placebo in mpox patients with active lesions. This recommendation does not affect other authorised uses of Tecovirimat SIGA.